Aclarion, Inc. (NASDAQ:ACON)
| Market Cap | $3.52M-79.8% |
| Revenue (ttm) | $98.56K+46.0% |
| Net Income | -$10.11M-37.9% |
| EPS | -$5.61+99.7% |
| Shares Out | 2.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,941 |
| Open | $1.25 |
| Previous Close | $1.42 |
| Day's Range | $1.22 - $1.25 |
| 52-Week Range | $1.22 - $9.36 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 17, 2027 |
About ACON
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Aclarion, Inc. Stock Analysis — InsiderScore
Aclarion, Inc. scored higher than 8% of companies evaluated by InsiderBuying, and ranked 54th out of 57 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Aclarion, Inc. bought $4.9K of stock across 1 purchase in the last 90 days, the largest of them $4.9K.
The average purchase added about 6% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 17, 2027Earnings report
$ACON stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ACON holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ACON's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ACON Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ACON patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ACON from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ACON
| VXFVanguard Extended Market ETF | $13.22K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ACON’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-2.0 since Nov 20Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
